Iftekhar Mahmood

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7808648/publications.pdf

Version: 2024-02-01

80 papers	1,908 citations	304368 22 h-index	288905 40 g-index
80 all docs	80 docs citations	80 times ranked	1422 citing authors

#	Article	IF	Citations
1	Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug developmentâ˜†â˜†â˜†. Advanced Drug Delivery Reviews, 2007, 59, 1177-1192.	6.6	145
2	Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins. Clinical Pharmacokinetics, 2005, 44, 331-347.	1.6	128
3	Prediction of drug clearance in children from adults: a comparison of several allometric methods. British Journal of Clinical Pharmacology, 2006, 61, 545-557.	1.1	121
4	Dosing in Children: A Critical Review of the Pharmacokinetic Allometric Scaling and Modelling Approaches in Paediatric Drug Development and Clinical Settings. Clinical Pharmacokinetics, 2014, 53, 327-346.	1.6	106
5	Interspecies Scaling of Protein Drugs: Prediction of Clearance from Animals to Humans. Journal of Pharmaceutical Sciences, 2004, 93, 177-185.	1.6	78
6	Interspecies scaling of renally secreted drugs. Life Sciences, 1998, 63, 2365-2371.	2.0	75
7	Pharmacokinetic Allometric Scaling of Antibodies: Application to the First-In-Human Dose Estimation. Journal of Pharmaceutical Sciences, 2009, 98, 3850-3861.	1.6	74
8	Prediction of Drug Clearance in Children: Impact of Allometric Exponents, Body Weight, and Age. Therapeutic Drug Monitoring, 2007, 29, 271-278.	1.0	73
9	Drug Interaction Studies of Therapeutic Proteins or Monoclonal Antibodies. Journal of Clinical Pharmacology, 2007, 47, 1540-1554.	1.0	69
10	Theoretical Versus Empirical Allometry: Facts Behind Theories Application to Pharmacokinetics. Journal of Pharmaceutical Sciences, 2010, 99, 2927-2933.	1.6	68
11	Selection of the First-Time Dose in Humans: Comparison of Different Approaches Based on Interspecies Scaling of Clearance. Journal of Clinical Pharmacology, 2003, 43, 692-697.	1.0	62
12	Prediction of Clearance, Volume of Distribution and Half-life by Allometric Scaling and by use of Plasma Concentrations Predicted from Pharmacokinetic Constants: a Comparative Study. Journal of Pharmacy and Pharmacology, 2010, 51, 905-910.	1.2	52
13	Interspecies Scaling of Biliary Excreted Drugs: A Comparison of Several Methods**The views expressed in this article are those of the author and do not reflect the official policy of the FDA. No official support or endorsement by the FDA is intended or should be inferred.. Journal of Pharmaceutical Sciences, 2005, 94, 883-892.	1.6	44
14	Prediction of Drug Clearance in Children: an Evaluation of the Predictive Performance of Several Models. AAPS Journal, 2014, 16, 1334-1343.	2.2	44
15	Interspecies Scaling: Predicting Oral Clearance in Humans. American Journal of Therapeutics, 2002, 9, 35-42.	0.5	41
16	Application of Fixed Exponent 0.75 to the Prediction of Human Drug Clearance: An Inaccurate and Misleading Concept. Drug Metabolism and Drug Interactions, 2009, 24, 57-82.	0.3	37
17	A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling for the Prediction of Drug Clearance From Neonates to Adolescents. Journal of Clinical Pharmacology, 2019, 59, 189-197.	1.0	34
18	Prediction of human drug clearance from animal data: Application of the rule of exponents and â€˜fu corrected intercept methodâ€™ (FCIM). Journal of Pharmaceutical Sciences, 2006, 95, 1810-1821.	1.6	30

#	Article	IF	Citations
19	Prediction of Drug Clearance in Premature and Mature Neonates, Infants, and Children â‰¥2 Years of Age: A Comparison of the Predictive Performance of 4 Allometric Models. Journal of Clinical Pharmacology, 2016, 56, 733-739.	1.0	30
20	A comparative study of allometric scaling with plasma concentrations predicted by species-invariant time methods. , 1999, 20, 137-144.		26
21	Prediction of Clearance in Neonates and Infants (â‰¤ 3 Months of Age) for Drugs That Are Glucuronidated: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling. Journal of Clinical Pharmacology, 2017, 57, 476-483.	1.0	25
22	Integration of in Vitro Data and Brain Weight in Allometric Scaling to Predict Clearance in Humans: Some Suggestionsâ€. Journal of Pharmaceutical Sciences, 1998, 87, 527-529.	1.6	24
23	Evaluation of a morphine maturation model for the prediction of morphine clearance in children: how accurate is the predictive performance of the model?. British Journal of Clinical Pharmacology, 2011, 71, 88-94.	1.1	24
24	Role of Fixed Coefficients and Exponents in the Prediction of Human Drug Clearance: How Accurate are the Predictions from One or Two Species?. Journal of Pharmaceutical Sciences, 2009, 98, 2472-2493.	1.6	23
25	Prediction of Clearance and Volume of Distribution in the Obese from Normal Weight Subjects. Clinical Pharmacokinetics, 2012, 51, 527-542.	1.6	23
26	Misconceptions and issues regarding allometric scaling during the drug development process. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 843-854.	1.5	22
27	Population Pharmacokinetics with a Very Small Sample Size. Drug Metabolism and Drug Interactions, 2009, 24, 259-274.	0.3	21
28	Naive Pooledâ€“Data Approach for Pharmacokinetic Studies in Pediatrics With a Very Small Sample Size. American Journal of Therapeutics, 2014, 21, 269-274.	0.5	21
29	Prediction of Clearance and Dose of Midazolam in Preterm and Term Neonates: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling. American Journal of Therapeutics, 2019, 26, e32-e37.	0.5	20
30	Interspecies Scaling for the Prediction of Drug Clearance in Children. Clinical Pharmacokinetics, 2010, 49, 479-492.	1.6	19
31	Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance. Journal of Clinical Pharmacology, 2003, 43, 692-7.	1.0	19
32	Prediction of drug clearance in children 3 months and younger: an allometric approach. Drug Metabolism and Drug Interactions, 2010, 25, 25-34.	0.3	18
33	Prediction of drug clearance in children: a review of different methodologies. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 573-587.	1.5	17
34	Pharmacokinetic Considerations in Designing Pediatric Studies of Proteins, Antibodies, and Plasma-Derived Products. American Journal of Therapeutics, 2016, 23, e1043-e1056.	0.5	16
35	Clinical Pharmacology of Antibody-Drug Conjugates. Antibodies, 2021, 10, 20.	1.2	16
36	A population pharmacokinetic model of remifentanil in pediatric patients using body-weight-dependent allometric exponents. Drug Metabolism and Drug Interactions, 2013, 28, 231-237.	0.3	13

#	Article	IF	Citations
37	Considerations for Optimizing Dosing of Immunoglobulins Based on Pharmacokinetic Evidence. Antibodies, 2020, 9, 24.	1.2	13
38	Prediction of Human Drug Clearance from Two Species: A Comparison of Several Allometric Methods. Journal of Pharmaceutical Sciences, 2010, 99, 1601-1613.	1.6	12
39	Prediction of Clearance, Volume of distribution, and Half-life of Drugs in Extremely Low to Low Birth Weight Neonates: An Allometric Approach. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 601-610.	0.6	12
40	Limited Sampling Model for the Estimation of Pharmacokinetic Parameters in Children. Therapeutic Drug Monitoring, 2000, 22, 532-536.	1.0	11
41	Vertical allometry: Fact or fiction?. Regulatory Toxicology and Pharmacology, 2014, 68, 468-474.	1.3	10
42	Prediction of Human Glomerular Filtration Rate from Preterm Neonates to Adults: Evaluation of Predictive Performance of Several Empirical Models. AAPS Journal, 2016, 18, 445-454.	2.2	10
43	Age- and Bodyweight-dependent Allometric Exponent Model for Scaling Clearance and Maintenance Dose of Theophylline From Neonates to Adults. Therapeutic Drug Monitoring, 2018, 40, 635-641.	1.0	10
44	Prediction of Clearance of Monoclonal and Polyclonal Antibodies and Non-Antibody Proteins in Children: Application of Allometric Scaling. Antibodies, 2020, 9, 40.	1.2	10
45	Prediction of Clearance and Volume of Distribution in the Obese from Normal Weight Subjects. Clinical Pharmacokinetics, 2012, 51, 527-542.	1.6	10
46	A Bayesian Approach for the Estimation of Pharmacokinetic Parameters in Children. American Journal of Therapeutics, 2003, 10, 88-92.	0.5	9
47	Pharmacokinetic Allometric Scaling of Oligonucleotides. Nucleic Acid Therapeutics, 2011, 21, 315-321.	2.0	9
48	Transplacental Transfer of Hepatitis B Neutralizing Antibody during Pregnancy in an Animal Model: Implications for Newborn and Maternal Health. Hepatitis Research and Treatment, 2014, 2014, 1-7.	2.0	9
49	Mechanistic versus allometric models for the prediction of drug clearance in neonates (<3 months) Tj ETQq1 1 0.784314 rgBT /Ove	1.0	9
50	Clinical Pharmacology Review of Plasmaâ€derived and Recombinant Protein Products: CBER Experience and Perspectives on Modelâ€informed Drug Development. Haemophilia, 2019, 25, e240-e246.	1.0	8
51	Extrapolation of Drug Clearance in Children â‰¥â€‰2ÂYears of Age from Empirical Models Using Data from Children (>â€‰2ÂYears) and Adults. Drugs in R and D, 2020, 20, 1-10.	1.1	8
52	Methods to determine pharmacokinetic profiles of therapeutic proteins. Drug Discovery Today: Technologies, 2008, 5, e65-e69.	4.0	7
53	Interspecies scaling of biliary excreted drugs: prediction of human clearance and volume of distribution. Drug Metabolism and Drug Interactions, 2012, 27, 157-64.	0.3	7
54	Multistep Unified Models Using Prior Knowledge for the Prediction of Drug Clearance in Neonates and Infants. Journal of Clinical Pharmacology, 2018, 58, 877-884.	1.0	7

#	Article	IF	Citations
55	Prediction of Clearance in Children from Adults Following Drugâ€“Drug Interaction Studies: Application of Age-Dependent Exponent Model. Drugs in R and D, 2020, 20, 47-54.	1.1	7
56	Response to the comments of Professors Anderson & Holford. British Journal of Clinical Pharmacology, 2011, 72, 521-523.	1.1	6
57	Prediction of drug concentration-time data in humans from animals: a comparison of three methods. Xenobiotica, 2012, 42, 756-765.	0.5	6
58	Passive Immunoprophylaxis for the Protection of the Mother and Her Baby: Insights from In Vivo Models of Antibody Transport. Journal of Immunology Research, 2017, 2017, 1-8.	0.9	6
59	Initiation of Pediatric Clinical Trials for Coagulation Factors: Application of Pharmacokinetics and Allometry to Firstâ€inâ€Pediatric Dose Selection. Journal of Clinical Pharmacology, 2019, 59, 829-834.	1.0	5
60	A GFR-Based Method to Predict the Effect of Renal Impairment on the Exposure or Clearance of Renally Excreted Drugs: A Comparative Study Between a Simple GFR Method and a Physiologically Based Pharmacokinetic Model. Drugs in R and D, 2020, 20, 377-387.	1.1	5
61	Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Peptides: When Is the Assessment of Certain Factors Warranted?. Antibodies, 2022, 11, 1.	1.2	5
62	Prediction of glucuronidated drug clearance in pediatrics (â‰¤5 years): An allometric approach. European Journal of Drug Metabolism and Pharmacokinetics, 2015, 40, 53-59.	0.6	4
63	Population Pharmacokinetics: Some Observations in Pediatric Modeling for Drug Clearance. Clinical Pharmacokinetics, 2017, 56, 1567-1576.	1.6	4
64	Interspecies Scaling of Antibodyâ€“Drug Conjugates (ADC) for the Prediction of Human Clearance. Antibodies, 2021, 10, 1.	1.2	4
65	A Single Animal Species-Based Prediction of Human Clearance and First-in-Human Dose of Monoclonal Antibodies: Beyond Monkey. Antibodies, 2021, 10, 35.	1.2	4
66	Allometric scaling and prediction of concentration-time profiles of coagulation factors in humans from animals. Xenobiotica, 2013, 43, 774-779.	0.5	3
67	Prediction of Antimalarial Drug Clearance in Children: A Comparison of Three Different Interspecies Scaling Methods. European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41, 767-775.	0.6	3
68	Population pharmacokinetics of immunoglobulin intravenous preparation in very low birth weight neonates. International Immunopharmacology, 2020, 80, 106192.	1.7	3
69	Spreadsheetâ€Based Minimal Physiological Models for the Prediction of Clearance of Therapeutic Proteins in Pediatric Patients. Journal of Clinical Pharmacology, 2021, 61, S108-S116.	1.0	3
70	Prediction of drug concentration-time profiles of therapeutic proteins in humans from animals. Xenobiotica, 2013, 43, 153-160.	0.5	2
71	Effect of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Antibodyâ€“Drug Conjugates (ADCs). Antibodies, 2021, 10, 40.	1.2	2
72	Selegiline transdermal system Somerset. Current Opinion in Investigational Drugs, 2002, 3, 1230-3.	2.3	2

#	Article	IF	Citations
73	Prediction of tissue concentrations of monoclonal antibodies in mice from plasma concentrations. Regulatory Toxicology and Pharmacology, 2018, 97, 57-62.	1.3	1
74	Considerations for pharmacokinetic assessment of immunoglobulins: Gammagard in very low birth weight neonates with and without baseline-correction. International Immunopharmacology, 2020, 82, 106358.	1.7	1
75	Selection of the First-Time Dose in Humans: Comparison of Different Approaches Based on Interspecies Scaling of Clearance. Journal of Clinical Pharmacology, 2003, 43, 692-697.	1.0	1
76	Pediatric Physiology. , 2016, , 13-22.		1
77	A Simple Method for the Prediction of Human Concentrationâ€“Time Profiles and Pharmacokinetics of Antibodyâ€“Drug Conjugates (ADC) from Rats or Monkeys. Antibodies, 2022, 11, 42.	1.2	1
78	A comparison of simple allometric and maturation models for the prediction of morphine clearance in pediatrics. Drug Metabolism and Drug Interactions, 2011, 26, 71-7.	0.3	0
79	Application of Allometric Principles in Pediatric Drug Development. , 2016, , 65-81.		0
80	Modelâ€Based Evaluation of Linear Limited and Bayesian Sparse Sampling for Therapeutic Monitoring of Recombinant Coagulation Factor IX. Journal of Clinical Pharmacology, 2020, 60, 1453-1460.	1.0	0